This drug manual is provided for use in patients with hypertensive emergency (also referred to as hypertensive crisis or malignant hypertension). Hypertensive emergency is defined as significantly elevated blood pressure (systolic pressure ≥180 mmHg and/or diastolic pressure ≥120 mmHg) with concurrent signs of acute organ damage or failure. Any of the drugs listed below may be used to treat hypertensive emergencies. The desired time to action, contraindications, and risk of adverse effects should guide the choice of agent.
Calcium channel blockers (CCB)
Clevidipine
Drug | Clevidipine |
Brand names | Cleviprex ® |
Indications | Hypertension and hypertensive emergency. Treatment of postoperative hypertension. |
Mechanism of action | Ultra-short-acting calcium channel blocker (CCB). Half-life: 5 minutes. Rapidly inactivated by esterases. |
Effects | • Clevidipine is a dihydropyridine L-type calcium channel blocker. Clevidipine is highly selective for vascular smooth muscle cells and has little or no effect on myocardial contractility or conduction. Clevidipine reduces mean arterial blood pressure (MAP) by decreasing systemic vascular resistance (SVR). Clevidipine does not reduce cardiac filling pressure (pre-load), since it has no effects on the venous capacitance vessels. Hence, Clevidipine reduces blood pressure without affecting cardiac filling pressures. • Clevidipine is more effective than nitroglycerin, nitroprusside, and nicardipine in hypertensive emergencies. |
Time to onset of action | 2-4 minutes |
Duration of action | 5-15 minutes |
Delivery | IV (infusion). |
Dose | Initial dose: 1-2 mg/h IV. Increase as necessary. Rapid titration is possible. Maximum dose: 21 mg/h IV. Common therapeutic dose: 4-6 mg/h. Clevidipine is administered in lipid emulsion (containing soy, egg), of which the maximum dose per 24 hours is 1000 mL. |
Adverse effects | Headache. Nausea. Fever. Atrial fibrillation. Worsening of heart failure. |
Caution | • Used cautiously in patients with acute heart failure. • Clevidipine can cause reflex tachycardia. • Contraindicated in severe aortic stenosis due to risk of hypotension. |
Nicardipine
Drug | Nicardipine |
Brand names | Cardene ® |
Indications | Hypertension, hypertensive emergency/crisis. Pregnancy-induced hypertension. Angina pectoris Prinzmetal’s angina |
Mechanism of action | Nicardipine is a dihydropyridine calcium-channel blocker (CCB). Nicardipine inhibits the influx of extracellular calcium in the myocardial and peripheral vascular smooth muscle cell membranes, thus inhibiting the contraction of smooth muscle cells. As compared with nitroprusside, nicardipine induces relatively greater venodilation than arteriolar dilation. |
Effects | Nicardipine causes dilation of the coronary and systemic arteries, decreases total peripheral resistance, decreases systemic blood pressure, and decreases afterload. Nicardipine has antianginal and antihypertensive effects. |
Time to onset of action | 5 to 15 minutes |
Duration of action | 1.5 to 5 hours |
Delivery | IV |
Dose | 5–15 mg/hour IV infusion. Higher doses (up to 30 mg/hour) may be required in some patients. |
Adverse effects | Tachycardia. Headache. Flushing. Edema. Dizziness. |
Caution | Should be used cautiously in patients with myocardial ischemia and/or heart failure. |
ACE inhibitors
Enalaprilat
Enalaprilat is rarely used in hypertensive crisis due to its slow onset, prolonged duration of effect, and significant individual variations in its effect.
«
Drug | Enalaprilat |
Brand names | Vasotec IV ® |
Indications | Hypertension and hypertensive emergency. Acute left ventricular failure. |
Mechanism of action | Enalaprilat is the active metabolite (ester) of enalapril, an angiotensin-converting enzyme (ACE) inhibitor. Enalaprilat lowers blood pressure by inhibiting ACE. |
Effects | • The hypotensive effect of enalaprilat depends on plasma volume and plasma renin activity. Volume depletion and high plasma renin activity increase the effect of enalaprilat and may cause severe hypotension. |
Time to onset of action | 15 to 30 minutes. |
Peak effect | Within hours. |
Duration of effect | 8 to 24 hours |
Delivery | IV |
Dose | Initial dose: 1.25 mg IV. Increase as necessary. Maximum dose: 5 mg IV every six hours. |
Adverse effects | Severe hypotension. |
Contraindications | • Contraindicated in pregnancy, severe renal artery stenosis, severe hyperkalemia. • Avoid in acute heart failure and acute myocardial infarction. |
Beta-blockers
Esmolol
Drug | Esmolol |
Brand names | Brevibloc ® |
Indications | Short-term control of ventricular rate (including perioperative tachycardia) and hypertension (including hypertensive emergency, perioperative hypertension). |
Mechanism of action | • Relatively cardioselective (beta-1 receptor blocker) beta-blocker with ultra-short acting effect. • Half-life: 9 minutes. |
Effects | • Esmolol is a beta-adrenergic receptor blocker. • Esmolol lowers blood pressure immediately (within 1 minute). • Esmolol may also be used to control supraventricular tachycardia (rate control). • Esmolol may be used to reduce myocardial ischemia in the CCU or ICU. |
Time to onset of action | 1 minute |
Duration of action | 20-30 minutes |
Delivery | IV |
Dose | Loading dose: 500 μg/kg bolus over 1 minute. Infusion start dose: 25–50 μg/kg/min. Maximum infusion dose: 300 μg/kg/min. Bolus doses of 300 μg/kg can be repeated during infusion. |
Adverse effects | Flushing. Nausea. Bronchospasm. AV block. |
Caution | • Avoid in acute heart failure. • May cause bradycardia. |
Labetalol
Drug | Labetalol |
Brand names | Trandate ® |
Indications | Myocardial ischemia. Hypertension. Hypertensive emergency, including in pregnancy. Postoperative hypertension. |
Mechanism of action | Combined beta-adrenergic and alpha-adrenergic blocker with rapid onset of action. Labetalol has less antihypertensive efficacy compared with nicardipine. Labetalol is safe in patients with coronary artery disease since it does not increase heart rate and reduces myocardial oxygen consumption. Time to onset of action: 5 minutes. |
Effects | Lowers blood pressure, reduces heart rate, myocardial oxygen consumption, and myocardial contractility. |
Time to onset of action | 5 to 10 minutes |
Duration of action | 2 to 4 hours |
Delivery | IV |
Dose | Can be given as repeated intravenous bolus injections or as a constant-dose infusion. Bolus regimen: • 20 mg IV bolus over 2 minutes, followed by 20 to 80 mg every 10 minutes to a total dose of 300 mg. Infusion regimen: • 0.5–2 mg/minute IV infusion. Higher doses are sometimes required. |
Adverse effects | Vomiting. Dizziness. Nausea. Atrioventricular blocks (AV blocks). Orthostatic hypotension. Paresthesias (scalp tingling). Bronchospasm. |
Caution | • Avoided in hypertensive emergencies with left ventricular failure (due to negative inotropic effect). • Used cautiously in patients with asthma (due to risk of bronchospasm). • Used cautiously in bradycardia due to negative chronotropic effect. • In patients with pheochromocytoma, cocaine, or methamphetamine overdose, prior treatment with alpha blockade is necessary before administering labetalol (risk of elevating blood pressure in these settings). |
Metoprolol
Drug | Metoprolol |
Brand names | Dutoprol ®, Kapspargo ®, Lopressor ®, Lopressor HCT ®, Toprol ®, Seloken ® |
Indications | Myocardial ischemia. Hypertension périopératoire. |
Mechanism of action | Bêta-1 bloquant adrénergique. |
Effects | Réduit la pression artérielle, diminue la fréquence cardiaque, la consommation d’oxygène myocardique et la contractilité myocardique. Effet hypotenseur moins prononcé que l’esmolol et le labétalol. |
Time to onset of action | 20 minutes |
Duration of action | 5 à 8 heures |
Delivery | IV |
Dose | 1,25 à 5 mg IV suivi de 2,5 à 15 mg IV toutes les 3 à 6 heures. |
Adverse effects | Vomissements. Vertiges. Nausées. Blocs auriculo-ventriculaires (blocs AV). Hypotension orthostatique. Paresthésies (picotements du cuir chevelu). Bronchospasme. |
Caution | • À éviter dans les urgences hypertensives avec insuffisance cardiaque aiguë. • Utilisé avec prudence chez les patients asthmatiques (en raison du risque de bronchospasme). • Utilisé avec prudence en cas de bradycardie en raison de l’effet chronotrope négatif. |
Agonistes des récepteurs dopaminergiques
Fenoldopam
Drug | Fenoldopam |
Brand names | Corlopam ® |
Indications | Gestion à court terme de l’hypertension, y compris l’urgence hypertensive. |
Mechanism of action | • Agoniste systémique des récepteurs Dopamine-1 (D1). • Réduit la pression artérielle tout en maintenant ou en augmentant la perfusion rénale. |
Effects | Les agonistes des récepteurs Dopamine-1 abaissent la pression artérielle systémique et augmentent la perfusion rénale. |
Time to onset of action | 5 à 10 minutes |
Duration of action | 30 à 60 minutes |
Delivery | IV |
Dose | Dose initiale de perfusion : 0,1 μg/kg/minute IV. Ajustée à intervalles de 15 minutes. Dose maximale de perfusion : 1,6 μg/kg/minute |
Adverse effects | Maux de tête. Bouffées de chaleur. Tachycardie. Nausées. Hypokaliémie. Augmentation de la pression intraoculaire chez les patients atteints de glaucome. |
Caution | Utilisé avec prudence chez les patients atteints de glaucome ou ayant une pression intracrânienne élevée. |
Agonistes alpha
Clonidine
Drug | Clonidine |
Brand names | Catapresan ®, Catapres ®, Dixarit ®, Catapres-TTS ®, Catapres-TTS-1 ®, Duraclon ®, Kapvay ® |
Indications | • Agitated delirium • Analgesia • Hypertension, hypertensive crisis/emergency |
Mechanism of action | Clonidine is primarily a centrally acting alpha-2 agonist. Stimulation of alpha-2 adrenoceptors in the ventromedial and rostral-ventrolateral areas of the medulla results in the blood pressure-lowering effect. |
Effects | Potent blood pressure-lowering effect. Pain relief. |
Delivery | IV, IM, PO, transdermal |
Dose | Injection IV: • 150 μg in 1 ml vial. Dilute with 10 ml of normal saline and give by slow injection over 5-10 minutes. Dilute immediately before use. PO: Alternatives: Dixarit 25 μg tablets. Catapres 150 μg tablets. Dose: 75 μg daily increased as required to up to 900 μg/day. Transdermal (one patch lasts for a week): • Catapres TTS-1 (0.1 mg/24 hrs). • Catapres TTS-2 (0.2 mg/24 hrs) • Catapres TTS-3 (0.3 mg/24 hrs) Dosage in renal failure and renal replacement therapy: Dose as in normal renal function |
Adverse effects | Excessive sedation. Confusion. Hallucinations. Hypotension. Bradycardia. AV-block. Constipation. |
Contraindications | Bradycardia. |
Caution | • Clonidine may induce severe hypotension. • Clonidine is not recommended in most patients with severe cardiovascular disease or in those who are otherwise hemodynamically unstable. The benefit of its administration in these patients should be carefully balanced against the potential risks resulting from hypotension. • Withdrawal of clonidine may lead to rebound hypertension. Withdraw slowly. • Simultaneous use of tricyclic antidepressants reduces the effect of clonidine. • Clonidine increases the CNS-depressive effects of alcohol and sedatives. |
Nitric oxide (NO) inducing drugs
Nitroglycerin
Patients using nitroglycerin regularly may have developed tolerance and require higher doses, or alternatively nitroprusside, to achieve the desirable blood pressure-lowering effect.
Drug | Nitroglycerin |
Brand names | Gonitro ®, Minitran ®, Mylan-nitro ®, Nitro-bid ®, Nitro-dur ®, Nitroject ®, Nitrolingual ®, Nitromist ®, Nitrostat ®, Rectiv ®, Trinipatch ® |
Indications | Œdème pulmonaire, insuffisance cardiaque congestive. Angine de poitrine. Hypertension, crise hypertensive/urgence hypertensive. Hypertension pulmonaire. Contrôle de la pression artérielle. |
Mechanism of action | La nitroglycérine fournit de l’oxyde nitrique (NO) qui induit une vasodilatation (des artérioles et des veines) via la génération de GMP cyclique, qui active ensuite les canaux potassiques sensibles au calcium dans la membrane cellulaire. La nitroglycérine est similaire dans son action et sa pharmacocinétique au nitroprussiate, bien que ce dernier soit plus puissant. |
Effects | Antihypertenseur. Antiangineux. |
Time to onset of action | 2 à 5 minutes |
Duration of action | 5 à 10 minutes |
Delivery | IV |
Dose | Dose initiale de perfusion : 5 μg/min. Augmenter de 5-10 μg/min toutes les 5 min jusqu’à la pression artérielle souhaitée. Dose maximale : 100 μg/min. Délai d’action : 2 à 5 minutes Durée d’action : 5 à 10 minutes. |
Adverse effects | Céphalée (vasodilatation cérébrale). Tachycardie (due à l’activation sympathique réflexe). Nausées. Vomissements. Bouffées de chaleur. Palpitations. Tolérance avec utilisation prolongée. Méthémoglobinémie. Hypoxémie. |
Caution | Procéder avec prudence dans les conditions dépendantes de la postcharge. |
Nitroprussiate
Drug | Nitroprusside |
Brand names | Nipride ®, Nipride RTU ®, Nitropress ®. |
Indications | Œdème pulmonaire, insuffisance cardiaque congestive. Angine de poitrine. Hypertension, crise hypertensive/urgence hypertensive. Hypertension pulmonaire. Contrôle de la pression artérielle. |
Mechanism of action | Le nitroprussiate fournit de l’oxyde nitrique (NO) qui induit une vasodilatation des artérioles et des veines via la génération de GMP cyclique, qui active ensuite les canaux potassiques sensibles au calcium dans la membrane cellulaire. Délai d’action : 1 minute. Durée d’action : <10 minutes. |
Effects | Abaissement puissant de la pression artérielle. Effet antiangineux. Réduit la postcharge et la précharge. Efficace dans l’œdème pulmonaire. Peut provoquer une hypotension sévère. |
Time to onset of action | 30 secondes à 1 minute |
Duration of action | 1 à 10 minutes |
Delivery | IV |
Dose | Perfusion : Dose initiale : 0,25 à 0,5 μg/kg/minute. Augmentée si nécessaire (par paliers de 0,5 μg/kg/min). Dose maximale : 8-10 μg/kg/minute. Dose maximale courante : 3 μg/kg/minute. La dose maximale (10 μg/kg/minute) ne doit jamais être utilisée pendant plus de 10 minutes. Administrer du thiosulfate de sodium (cyanure en thiocyanate) et arrêter la perfusion de nitroprussiate si une toxicité au cyanure est suspectée. |
Adverse effects | • Nausées. Vomissements. Agitation. Spasmes musculaires. Transpiration. Bouffées de chaleur. • Une utilisation prolongée à haute dose peut provoquer une toxicité au thiocyanate et au cyanure. Le nitroprussiate est métabolisé en cyanure. La toxicité au cyanure peut être fatale (doit être suspectée si le patient développe un état mental altéré et une acidose lactique). Les issues fatales sont rares. L’insuffisance rénale augmente le risque de toxicité au cyanure. La toxicité au cyanure nécessite des doses >2 μg/kg/minute. Utiliser la dose la plus faible possible, éviter une utilisation prolongée (<2-3 jours), et surveiller le patient de près pour éviter la toxicité au cyanure. • Réduction dose-dépendante de la perfusion coronaire et rénale. • Élévation dose-dépendante de la pression intracrânienne (PIC) et réduction du flux sanguin cérébral. |
Caution | • Utilisé avec prudence chez les patients présentant une pression intracrânienne élevée ou une azotémie. • Ne doit pas être administré aux femmes enceintes. • Ne doit pas être administré aux patients atteints d’atrophie optique de Leber. |
Autres médicaments
Phentolamine
Drug | Phentolamine |
Brand names | Oraverse ®, Rogitine ® |
Indications | Hypertensive crisis. |
Mechanism of action | Phentolamine is a non-selective alpha-adrenergic blocker. Phentolamine reduces blood pressure while increasing catecholamine activity. |
Effects | Primarily causes afterload reduction. |
Time to onset of action | 1 to 2 minutes |
Duration of action | 10 to 30 minutes |
Delivery | IV |
Dose | Bolus injection: 5 to 15 mg every 5 to 15 minutes as necessary. Continuous infusion: Start infusion at 0.1 mg/min and increase in increments of 0.1 mg. |
Adverse effects | Tachycardia. Flushing. Headache. Nausea. Vomiting. |
Caution | Rarely used unless the patient has a confirmed diagnosis of pheochromocytoma Treatment of hypertension associated with pheochromocytoma; treatment of dermal necrosis after extravasation of drugs with α-adrenergic effects. |
Hydralazine
Not preferred for hypertensive emergencies due to the high risk of reflex sympathetic stimulation.
Drug | Hydralazine |
Brand names | Apresoline ®, Bidil ® |
Mechanism of action | • Induces arteriolar vasodilation. No effect on venous circulation. • May cause reflex sympathetic stimulation (can be counteracted with simultaneous administration of beta-blockers). |
Effects | Induces arteriolar vasodilation without effects on venous circulation. The reduction in systemic vascular resistance (SVR) is rapid and may cause reflex sympathetic stimulation, including tachycardia. May therefore induce or worsen angina pectoris. The rapid reduction of afterload is desired in conditions requiring afterload reduction. |
Time to onset of action | 10-30 minutes. |
Duration of action | <4 hours. |
Delivery | IV or IM. |
Dose | Injections • IV: 10–40 mg every 4–6 hours • IM: 10–20 mg every 4–6 hours. Infusion • Afterload reduction: Start infusion at 1 mg/hour. Increase by 0.5 mg/hour every 20 min to desired blood pressure. Maximum infusion rate 5 mg/hour. • Antihypertensive treatment: Start infusion at 5 mg/hour. Increase by 2.5 mg/hour every 20 min to desired blood pressure. Maximum infusion rate 25 mg/hour. |
Adverse effects | Tachycardia. Flushing. Headache. Angina pectoris. |
Caution | Heart failure. Angina pectoris (ischemic heart disease). |
References
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Hypertension 2018; 71:e140-e144]. Hypertension 2018; 71:e13-e115.
- Marik PE, Varon J. Hypertensive crises: Challenges and management. Chest 2007; 131:1949.
- Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206.
- Varon J. Treatment of acute severe hypertension: Current and newer agents. Drugs 2008; 68:283.